Boston, Massachusetts, June 03, 2025 (GLOBE NEWSWIRE) -- With the changes of the times and the advancement of technology, people's…
MUMBAI, India, June 3, 2025 /PRNewswire/ -- Sameer Kanodia, Managing Director and CEO, Lumina Datamatics, and Vice Chairman and CEO,…
June 03, 2025 01:00 ET | Source: argenx SE June 3, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX),…
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare…
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic…